β¨ Medicines Consent Notices
24 APRIL 2008 NEW ZEALAND GAZETTE, No. 76
2113
Dosage Form: Oral gel
New Zealand Sponsor: Dentsply New Zealand
Manufacturer: Recipharm Karlskoga AB, Bjorkborn, Karlskoga, Sweden
Dated this 22nd day of April 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2865
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Abelcet
Active Ingredient: Amphotericin B 5mg/mL
Dosage Form: Emulsion for infusion
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Enzon Pharmaceuticals, Inc, Indianapolis, United States of America
Note: This consent is valid for two years from the date of this publication.
Dated this 22nd day of April 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2867
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 11.43mg equivalent to 10mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 20.57mg equivalent to 18mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 28.57mg equivalent to 25mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 45.71mg equivalent to 40mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 5.71mg equivalent to 5mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 68.56mg equivalent to 60mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Dated this 22nd day of April 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2866
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2008, No 76
Gazette.govt.nz —
NZ Gazette 2008, No 76
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare22 April 2008
Medicines, Distribution, Consent, Oral gel, Medicines Act 1981
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare22 April 2008
Medicines, Distribution, Provisional Consent, Emulsion for infusion, Medicines Act 1981
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare22 April 2008
Medicines, Distribution, Changed Medicine, Capsule, Medicines Act 1981
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate